Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anesiva, Inc.
Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
February 29th, 2008
Anesiva, Inc. (NASDAQ:ANSV) reported 2007 fourth quarter and year-end financial results and accomplishments and outlined its objectives for 2008 based on commercialization plans for FDA-approved Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, as well as clinical development milestones for Adlea(TM), the company's long-acting, localized, non-opioid analgesic drug candidate. "We are preparing on multiple fronts for a successful commercial introduction for Zingo in the second quarter by driving product demand through multiple initiatives and direct contact with our target customers," said John P. McLaughlin, chief executive officer of...
Source: Health Business Week (2008-02-29)
|
